Fluvoxamine (CAS 54739-18-3) / Antidepressant

Fluvoxamine (CAS 54739-18-3) is a high-purity pharmaceutical API classified as a classic SSRI, featuring a diarylpropylamine molecular structure with selective affinity for serotonin transporters. It acts by specifically inhibiting the reuptake of serotonin in the central nervous system—elevating synaptic serotonin levels to regulate mood, relieve anxiety, and restore emotional balance. Unlike non-selective antidepressants, it minimizes off-target effects on other neurotransmitters, ensuring better tolerability for long-term use.

This premium API caters to the core needs of psychiatric drug manufacturers, antidepressant formulation developers, and clinical supply chains. Widely applied in developing treatments for major depressive disorder, obsessive-compulsive disorder (OCD), and social anxiety disorder, it aligns with the demand for evidence-based, well-tolerated mood disorder therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, guaranteeing consistency for clinical applications. For businesses focusing on reliable psychiatric pharmaceutical raw materials, this Fluvoxamine API serves as a critical component for advancing effective and safe antidepressant medication development.